艾伯维公司近日宣布,其丙肝治疗药物Maviret®(格卡瑞韦/哌仑他韦组合)已获得欧洲药品管理局人用药品委员会(CHMP)的积极意见,该意见支持将该药物用于治疗急性丙型肝炎感染。这一进展为拓宽Maviret®的适用范围、惠及更多患者群体铺平了道路。
艾伯维公司近日宣布,其丙肝治疗药物Maviret®(格卡瑞韦/哌仑他韦组合)已获得欧洲药品管理局人用药品委员会(CHMP)的积极意见,该意见支持将该药物用于治疗急性丙型肝炎感染。这一进展为拓宽Maviret®的适用范围、惠及更多患者群体铺平了道路。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.